| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 01/28/2003 | US6511801 HIV-1 group O strain gp160 env precursor protein comprising the amino acid sequence of SEQ ID NO:100 |
| 01/28/2003 | US6511699 Enzymes with improved phytase activity |
| 01/28/2003 | US6511676 Forming cisplatin and ethanol buffered solution; combining with a negatively charged phosphatidyl glycerol lipid deriva-tive; able to reach primary tumors and their metastases after intravenous injection; breast and prostate cancer |
| 01/28/2003 | US6511667 Attenuated dengue-2 virus vaccine |
| 01/28/2003 | US6511665 Antibodies to interleukin-1 receptors |
| 01/28/2003 | CA2417572A1 Process for producing recombined protein |
| 01/28/2003 | CA2417547A1 Novel amylolytic enzyme extracted from bacillus sp. a 7-7 (dsm 12368) and washing and cleaning agents containing this novel amylolytic enzyme |
| 01/28/2003 | CA2318432C The use of isolated domains of type iv collagen to modify cell and tissue interactions |
| 01/28/2003 | CA2253654C Novel nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor |
| 01/28/2003 | CA2082476C Process for producing flavine nucleotides |
| 01/28/2003 | CA2077590C Recombinant dna coding for a protein with endochitinase activity |
| 01/28/2003 | CA2072008C Immunologically active proteins from borrelia burgdorferi, related test kits which contain these proteins and are suitable for detecting antibodies in test fluids, and the use of these proteins as vaccines against infections caused by borrelia strains |
| 01/27/2003 | CA2391642A1 Identification and use of molecules implicated in pain |
| 01/27/2003 | CA2391219A1 Identification and use of molecules implicated in pain |
| 01/27/2003 | CA2391216A1 Identification and use of molecules implicated in pain |
| 01/27/2003 | CA2391112A1 Identification and use of molecules implicated in pain |
| 01/24/2003 | WO2002008456A2 Method for identifying metastatic tumor cells |
| 01/24/2003 | CA2416697A1 Method for identifying metastasizing tumor cells |
| 01/23/2003 | WO2003006996A2 Natural ligand of gpcr chemr23 and uses thereof |
| 01/23/2003 | WO2003006995A2 Method for identifying substances which modulate interleukin 4 (il-4) signaling |
| 01/23/2003 | WO2003006988A1 Cardiovascular safety assay |
| 01/23/2003 | WO2003006950A2 Cells of the cardiomyocyte lineage produced from human pluripotent stem cells |
| 01/23/2003 | WO2003006692A1 Internal calibration standards for electrophoretic analyses |
| 01/23/2003 | WO2003006691A1 Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells |
| 01/23/2003 | WO2003006690A1 Use of urokinase gene amplification as a marker |
| 01/23/2003 | WO2003006686A1 Bioassay for myostatin |
| 01/23/2003 | WO2003006675A2 Methods and devices based upon a novel form of nucleic acid duplex on a surface |
| 01/23/2003 | WO2003006669A2 Efficient methods for assessing and validating candidate protein-based therapeutic molecules encoded by nucleic acid sequences of interest |
| 01/23/2003 | WO2003006663A2 Method for producing deletion mutants |
| 01/23/2003 | WO2003006662A1 Anti-neoplastic viral agents |
| 01/23/2003 | WO2003006661A2 Transgenic plants expressing cobalamin binding proteins |
| 01/23/2003 | WO2003006660A1 Expression cassettes for the transgenic expression of nucleic acids |
| 01/23/2003 | WO2003006659A2 Plant transcriptional repressor, proteic nuclear factors binding thereto, and uses thereof |
| 01/23/2003 | WO2003006657A2 Gene-regulatory elements for gene therapy, for the prevention and diagnosis of metastases and for the gene therapy of tumours |
| 01/23/2003 | WO2003006656A2 Process for the preparation of 2,4-dideoxyhexoses and 2,4,6-trideoxyhexoses |
| 01/23/2003 | WO2003006655A1 Sd1 gene participating in plant semidwarfing and utilization thereof |
| 01/23/2003 | WO2003006654A2 Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom |
| 01/23/2003 | WO2003006653A1 Mycoplasma spp. a39 |
| 01/23/2003 | WO2003006651A2 Vascular tissue preferred promoters |
| 01/23/2003 | WO2003006650A1 Method of purifying nucleic acid using nonwoven fabric and detection method |
| 01/23/2003 | WO2003006649A2 Expression system |
| 01/23/2003 | WO2003006648A2 S. pombe calnexin mutant strain |
| 01/23/2003 | WO2003006647A1 Allene oxide synthase and divinyl ether synthase from the cyp74-enzyme family isolated out of physcomitrella patens, the nucleotide sequences that code these synthases, and method for producing pathogen-resistant plants |
| 01/23/2003 | WO2003006646A1 Regulation of human aminopeptidase n |
| 01/23/2003 | WO2003006645A2 Method and composition for inhibiting heparanase activity |
| 01/23/2003 | WO2003006644A2 Lipase/acyltransferase |
| 01/23/2003 | WO2003006643A2 A p387l variant in protein tyrosine phosphatase-1b is associated with type 2 diabetes and impaired serine phosphorylation of ptp-1b in vitro |
| 01/23/2003 | WO2003006641A2 Epsti1, a gene induced by epithelial-stromal interaction in human breast cancer |
| 01/23/2003 | WO2003006640A1 A specific proliferation in tumour cell which can express antioncogene with high efficiency and the use of it |
| 01/23/2003 | WO2003006639A1 Cell and transgenic animal modelling human antigenic presentation and their uses |
| 01/23/2003 | WO2003006631A1 Leguminous bacterium having potentiated nitrogen fixation ability |
| 01/23/2003 | WO2003006623A2 Directed protein modificaiton by iterative sequence insertion |
| 01/23/2003 | WO2003006622A2 Nuclear fertility restorer genes and methods of use in plants |
| 01/23/2003 | WO2003006618A2 Nucleic acid-associated proteins |
| 01/23/2003 | WO2003006616A2 Pseudotyped adeno-associated viruses and uses thereof |
| 01/23/2003 | WO2003006612A2 Production of transduced hematopoietic progenitor cells |
| 01/23/2003 | WO2003006611A2 GPCs AS MODIFIERS OF THE IRRTK AND p21 PATHWAYS AND METHODS OF USE |
| 01/23/2003 | WO2003006609A2 Human cytokine receptor |
| 01/23/2003 | WO2003006608A2 Enhancement of transfection of dna into the liver |
| 01/23/2003 | WO2003006607A2 Inhibition of apoptosis process and improvement of cell performance |
| 01/23/2003 | WO2003006602A2 Subtilase variants |
| 01/23/2003 | WO2003006509A2 Human mini-antibody cytotoxic for tumor cells which express the erbb2 receptor |
| 01/23/2003 | WO2003006504A2 Allelic variants of gpr50 |
| 01/23/2003 | WO2003006502A2 Isolation, characterization, and use of a teleost potassium channel |
| 01/23/2003 | WO2003006501A2 G-csf conjugates |
| 01/23/2003 | WO2003006499A2 Survivin interacting protein tpr1 |
| 01/23/2003 | WO2003006497A2 Mutated photoproteins and their uses |
| 01/23/2003 | WO2003006496A2 Protein variants of neocarzinostatine and its homologues and their use |
| 01/23/2003 | WO2003006495A2 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket |
| 01/23/2003 | WO2003006493A2 Histidine phosphatase interacting protein with 180kd |
| 01/23/2003 | WO2003006492A2 Biologically active peptides |
| 01/23/2003 | WO2003006487A2 Modulation of phosphoinositide 3-kinase activity |
| 01/23/2003 | WO2003006485A2 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 01/23/2003 | WO2003006482A2 Use of specific t2r taste receptors to identify compounds that block bitter taste |
| 01/23/2003 | WO2003006480A1 Tetrahymena metallothionein gene promoter and its use |
| 01/23/2003 | WO2003006478A1 Oligonucleotide-containing pharmacological compositions and their use |
| 01/23/2003 | WO2003006477A1 IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
| 01/23/2003 | WO2003006471A1 Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands |
| 01/23/2003 | WO2003006104A2 Lymphatic endothelial cells materials and methods |
| 01/23/2003 | WO2003006103A2 Electrical field stimulation of eukaryotic cells |
| 01/23/2003 | WO2003006051A1 Use of corticotroph-derived glycoprotein hormone to induce lipolysis |
| 01/23/2003 | WO2003006047A2 Methods for reducing immunogenicity of polypeptides |
| 01/23/2003 | WO2003006045A2 Cxcl10 treatment of secondary tissue degeneration |
| 01/23/2003 | WO2003005964A2 Recombinant vsv for the treatment of tumor cells |
| 01/23/2003 | WO2003005957A2 Mutants of clostridium septicum alpha toxin and vaccines, antibodies, sera, and methods of treatment therewith |
| 01/23/2003 | WO2003005953A2 Viral proteins capable of binding lar |
| 01/23/2003 | WO2003005880A2 Replikin peptides and uses thereof |
| 01/23/2003 | WO2003005812A2 Modulation of metabolism of steroids and xenobiotics |
| 01/23/2003 | WO2003005811A1 Il-18 transgenic animal |
| 01/23/2003 | WO2003005810A2 Cloned non-human mammals from contact inhibited donor cells |
| 01/23/2003 | WO2003005809A1 Method of elevating glutamic acid content in plant and plants having elevated glutamic acid content |
| 01/23/2003 | WO2002098908A9 Osteoclastogenesis inhibitory factor, sequence coding for it and uses |
| 01/23/2003 | WO2002094867A8 Sequence of the photorhabdus luminescens strain tt01 genome and uses |
| 01/23/2003 | WO2002092822A3 Leaf specific gene promoter of coffee |
| 01/23/2003 | WO2002088302A3 Method for secreting proteins by bacteria, leader sequences and vectors for carrying out said method |
| 01/23/2003 | WO2002086058A3 Method for producing catalytic antibodies (variants), antigens for immunisation and nucleotide sequence |
| 01/23/2003 | WO2002083726A3 A novel zinc finger protein and uses thereof |
| 01/23/2003 | WO2002072827A9 Traf3-binding b cell-specific receptor |
| 01/23/2003 | WO2002070685A3 Method of modifying the genome of gram-positive bacteria by means of a novel conditionally negative dominant marker gene |
| 01/23/2003 | WO2002070676A3 Use of protein histidine phosphatase |